OTCMKTS:ATMS

Artemis Therapeutics Competitors

$0.30

0.00 (0.00 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.30

Now: $0.30▼

$0.30

50-Day Range

$0.23

MA: $0.32▼

$0.52

52-Week Range

$0.03

Now: $0.30▼

$2.00

VolumeN/A

Average Volume6,000 shs

Market Capitalization$1.55 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.38

Artemis Therapeutics (OTCMKTS:ATMS) Vs. ESI, WDFC, CBT, OEC, FTK, and ADES

Should you be buying ATMS stock or one of its competitors? Companies in the industry of "miscellaneous chemical products" are considered alternatives and competitors to Artemis Therapeutics, including Element Solutions (ESI), WD-40 (WDFC), Cabot (CBT), Orion Engineered Carbons (OEC), Flotek Industries (FTK), and Advanced Emissions Solutions (ADES).

Artemis Therapeutics vs. Element Solutions Stock

Artemis Therapeutics (OTCMKTS:ATMS) and Element Solutions (NYSE:ESI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Artemis Therapeutics and Element Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artemis Therapeutics	0	0	0	0	N/A
Element Solutions	0	2	2	0	2.50

Element Solutions has a consensus price target of $15.75, indicating a potential downside of 17.93%. Given Element Solutions' higher probable upside, analysts plainly believe Element Solutions is more favorable than Artemis Therapeutics.

Risk and Volatility

Artemis Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, Element Solutions has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Earnings and Valuation

This table compares Artemis Therapeutics and Element Solutions' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artemis Therapeutics	N/A	N/A	$-120,000.00	N/A	N/A
Element Solutions	$1.84 billion	2.58	$92.20 million	$0.88	21.81

Element Solutions has higher revenue and earnings than Artemis Therapeutics.

Insider & Institutional Ownership

85.1% of Element Solutions shares are owned by institutional investors. 7.5% of Artemis Therapeutics shares are owned by insiders. Comparatively, 13.2% of Element Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Artemis Therapeutics and Element Solutions' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artemis Therapeutics	N/A	N/A	-227.03%
Element Solutions	6.78%	10.02%	5.03%

Summary

Element Solutions beats Artemis Therapeutics on 10 of the 10 factors compared between the two stocks.

Artemis Therapeutics vs. WD-40 Stock

WD-40 (NASDAQ:WDFC) and Artemis Therapeutics (OTCMKTS:ATMS) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for WD-40 and Artemis Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WD-40	0	1	0	0	2.00
Artemis Therapeutics	0	0	0	0	N/A

WD-40 currently has a consensus price target of $295.00, indicating a potential upside of 5.33%. Given WD-40's higher possible upside, analysts clearly believe WD-40 is more favorable than Artemis Therapeutics.

Volatility and Risk

WD-40 has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Valuation and Earnings

This table compares WD-40 and Artemis Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WD-40	$423.35 million	9.06	$55.91 million	$4.40	63.65
Artemis Therapeutics	N/A	N/A	$-120,000.00	N/A	N/A

WD-40 has higher revenue and earnings than Artemis Therapeutics.

Insider and Institutional Ownership

90.4% of WD-40 shares are held by institutional investors. 2.1% of WD-40 shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares WD-40 and Artemis Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
WD-40	12.30%	33.97%	14.82%
Artemis Therapeutics	N/A	N/A	-227.03%

Summary

WD-40 beats Artemis Therapeutics on 8 of the 9 factors compared between the two stocks.

Artemis Therapeutics vs. Cabot Stock

Cabot (NYSE:CBT) and Artemis Therapeutics (OTCMKTS:ATMS) are both basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Cabot and Artemis Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabot	1	3	2	0	2.17
Artemis Therapeutics	0	0	0	0	N/A

Cabot currently has a consensus price target of $64.1667, indicating a potential upside of 20.70%. Given Cabot's higher possible upside, analysts clearly believe Cabot is more favorable than Artemis Therapeutics.

Volatility and Risk

Cabot has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cabot and Artemis Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabot	$2.61 billion	1.15	$-238,000,000.00	$2.08	25.56
Artemis Therapeutics	N/A	N/A	$-120,000.00	N/A	N/A

Artemis Therapeutics has lower revenue, but higher earnings than Cabot.

Insider and Institutional Ownership

86.2% of Cabot shares are held by institutional investors. 2.1% of Cabot shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cabot and Artemis Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cabot	-9.10%	11.67%	3.92%
Artemis Therapeutics	N/A	N/A	-227.03%

Summary

Cabot beats Artemis Therapeutics on 7 of the 10 factors compared between the two stocks.

Artemis Therapeutics vs. Orion Engineered Carbons Stock

Orion Engineered Carbons (NYSE:OEC) and Artemis Therapeutics (OTCMKTS:ATMS) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Profitability

This table compares Orion Engineered Carbons and Artemis Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion Engineered Carbons	2.47%	38.90%	4.96%
Artemis Therapeutics	N/A	N/A	-227.03%

Analyst Ratings

This is a summary of recent ratings for Orion Engineered Carbons and Artemis Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orion Engineered Carbons	1	0	2	0	2.33
Artemis Therapeutics	0	0	0	0	N/A

Orion Engineered Carbons currently has a consensus price target of $14.3333, indicating a potential downside of 24.36%. Given Orion Engineered Carbons' higher possible upside, analysts clearly believe Orion Engineered Carbons is more favorable than Artemis Therapeutics.

Valuation and Earnings

This table compares Orion Engineered Carbons and Artemis Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orion Engineered Carbons	$1.48 billion	0.78	$86.92 million	$1.87	10.13
Artemis Therapeutics	N/A	N/A	$-120,000.00	N/A	N/A

Orion Engineered Carbons has higher revenue and earnings than Artemis Therapeutics.

Insider and Institutional Ownership

86.0% of Orion Engineered Carbons shares are held by institutional investors. 1.3% of Orion Engineered Carbons shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Orion Engineered Carbons has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Summary

Orion Engineered Carbons beats Artemis Therapeutics on 9 of the 10 factors compared between the two stocks.

Artemis Therapeutics vs. Flotek Industries Stock

Flotek Industries (NYSE:FTK) and Artemis Therapeutics (OTCMKTS:ATMS) are both small-cap oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Flotek Industries and Artemis Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flotek Industries	-261.44%	-36.31%	-27.10%
Artemis Therapeutics	N/A	N/A	-227.03%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Flotek Industries and Artemis Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flotek Industries	0	0	0	0	N/A
Artemis Therapeutics	0	0	0	0	N/A

Valuation & Earnings

This table compares Flotek Industries and Artemis Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flotek Industries	$119.35 million	0.95	$-32,280,000.00	N/A	N/A
Artemis Therapeutics	N/A	N/A	$-120,000.00	N/A	N/A

Artemis Therapeutics has lower revenue, but higher earnings than Flotek Industries.

Insider & Institutional Ownership

29.1% of Flotek Industries shares are held by institutional investors. 9.9% of Flotek Industries shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Flotek Industries has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Summary

Flotek Industries beats Artemis Therapeutics on 5 of the 8 factors compared between the two stocks.

Artemis Therapeutics vs. Advanced Emissions Solutions Stock

Advanced Emissions Solutions (NASDAQ:ADES) and Artemis Therapeutics (OTCMKTS:ATMS) are both small-cap industrial products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Advanced Emissions Solutions and Artemis Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Emissions Solutions	-19.63%	15.49%	9.29%
Artemis Therapeutics	N/A	N/A	-227.03%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Advanced Emissions Solutions and Artemis Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Emissions Solutions	0	0	0	0	N/A
Artemis Therapeutics	0	0	0	0	N/A

Valuation & Earnings

This table compares Advanced Emissions Solutions and Artemis Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Emissions Solutions	$70.09 million	1.38	$35.54 million	N/A	N/A
Artemis Therapeutics	N/A	N/A	$-120,000.00	N/A	N/A

Advanced Emissions Solutions has higher revenue and earnings than Artemis Therapeutics.

Insider & Institutional Ownership

61.1% of Advanced Emissions Solutions shares are held by institutional investors. 14.9% of Advanced Emissions Solutions shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Advanced Emissions Solutions has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Summary

Advanced Emissions Solutions beats Artemis Therapeutics on 7 of the 8 factors compared between the two stocks.